https://pharminent.com/scholar-rocks-isemblyd-wins-first-muscle-targeted-sma-approval-at-310000-with-a-fracture-warning/ 2026-09-14T20:05:46Z Pharminent en Scholar Rock's Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning 2026-09-14T20:05:42Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-september-11-2026/ 2026-09-14T18:12:56Z Pharminent en Oncology Intelligence Digest • September 11, 2026 2026-09-14T18:12:53Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-september-11-2026/ 2026-09-14T18:09:53Z Pharminent en GLP-1 Competitive Market Digest • Weekly • September 11, 2026 2026-09-14T18:09:50Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-14-2026/ 2026-09-14T18:32:53Z Pharminent en Strategic News Watch • September 14, 2026 2026-09-14T17:15:08Z Blog https://pharminent.com/ 2026-09-14T12:10:29Z Pharminent en Market Intelligence 2026-09-14T12:10:27Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-september-12-2026/ 2026-09-14T12:02:48Z Pharminent en Week in Review • INTELLIGENCE BRIEF • September 12, 2026 2026-09-14T12:02:46Z Blog https://pharminent.com/week-in-review-page/ 2026-09-14T11:58:50Z Pharminent en Week in Review - Page 2026-09-14T02:25:09Z Blog